J. Paul Monk

4.4k total citations · 1 hit paper
58 papers, 3.3k citations indexed

About

J. Paul Monk is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. Paul Monk has authored 58 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in J. Paul Monk's work include Prostate Cancer Treatment and Research (15 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Treatment and Pharmacology (7 papers). J. Paul Monk is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Treatment and Pharmacology (7 papers). J. Paul Monk collaborates with scholars based in United States, Canada and Australia. J. Paul Monk's co-authors include Deborah M. Campoli-Richards, Paul Benfield, Peter A. Todd, Alan Ward, Allan H. Price, Michael A. Carducci, Nicholas J. Vogelzang, Susan Halabi, Eric J. Small and William Kevin Kelly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

J. Paul Monk

58 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ciprofloxacin

1988 639 citations Deborah M. Campoli-Richards, J. Paul Monk et al. Drugs profile →

Peers

Countries citing papers authored by J. Paul Monk

Since Specialization

Citations

This map shows the geographic impact of J. Paul Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Paul Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Paul Monk more than expected).

Fields of papers citing papers by J. Paul Monk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Paul Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Paul Monk. The network helps show where J. Paul Monk may publish in the future.

Co-authorship network of co-authors of J. Paul Monk

This figure shows the co-authorship network connecting the top 25 collaborators of J. Paul Monk. A scholar is included among the top collaborators of J. Paul Monk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Paul Monk. J. Paul Monk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer 2019 ·Prostate Cancer and Prostatic Diseases ·Melanie A. Krook, (unknown), Hui‐Zi Chen, Julie W. Reeser, Michele R. Wing, (unknown), (unknown), (unknown), Russell Bonneville, Eric Samorodnitsky, Jharna Miya, Aharon G. Freud, J. Paul Monk, Steven K. Clinton, Sameek Roychowdhury	5
2	A Mutation in the Mitochondrial Aspartate/Glutamate Carrier Leads to a More Oxidizing Intramitochondrial Environment and an Inflammatory Myopathy in Dutch Shepherd Dogs 2019 ·Journal of Neuromuscular Diseases ·G. Diane Shelton, Katie M. Minor, Kefeng Li, Jane C. Naviaux, J. Paul Monk, Lin Wang, (unknown), Ling T. Guo, Vito Porcelli, Ruggiero Gorgoglione, Francesco M. Lasorsa, Peter A. J. Leegwater, Antonio M. Persico, James R. Mickelson, Luigi Palmieri, Robert K. Naviaux	14
3	Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 2018 ·Cancer Treatment and Research Communications ·Primo N. Lara, Melissa Plets, Catherine M. Tangen, Erik Gertz, Nicholas J. Vogelzang, Maha Hussain, P. Twardowski, Mark Garzotto, J. Paul Monk, Michael A. Carducci, Amir Goldkorn, Philip C. Mack, Ian M. Thompson, Marta Van Loan, David I. Quinn	4
4	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421 2017 ·Clinical Genitourinary Cancer ·Guru Sonpavde, Gregory R. Pond, Melissa Plets, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Celestia S. Higano, Nicholas J. Vogelzang, Ian M. Thompson, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, David I. Quinn	5
5	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer 2013 ·Cancer ·Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel J. George, John F. Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, J. Paul Monk, Michael A. Carducci, Eric J. Small	15
6	Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). 2012 ·Journal of Clinical Oncology ·William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John F. Mahoney, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, J. Paul Monk, Eric J. Small	10
7	Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy 2011 ·Cancer ·J. Paul Monk, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen B. Kaplan, Tim A. Ahles, Lin Gu, Nicholas J. Vogelzang, William Kevin Kelly, Eric J. Small, (unknown)	16
8	A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. 2010 ·Journal of Clinical Oncology ·William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John F. Mahoney, Walter M. Stadler, M. J. Morris, Philip W. Kantoff, J. Paul Monk, Eric J. Small, (unknown)	113
9	A Combination of Tomato and Soy Products for Men With Recurring Prostate Cancer and Rising Prostate Specific Antigen 2008 ·Nutrition and Cancer ·Elizabeth M. Grainger, Steven J. Schwartz, Shihua Wang, (unknown), Thomas Boileau, Amy K. Ferketich, J. Paul Monk, Michael Gong, Robert Bahnson, Valerie DeGroff, Steven K. Clinton	59
10	The raf kinase inhibitor sorafenib inhibits Jak-STAT signal transduction in human immune cells 2008 ·Cancer Research ·(unknown), Sri Vidya Kondadasula, Thomas Olencki, J. Paul Monk, Gregory B. Lesinski, William E. Carson	2
11	High-Dose-Intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review 2008 ·Urology ·W. Kimryn Rathmell, J. Paul Monk	30
12	Information Seeking and Satisfaction With Physician–Patient Communication Among Prostate Cancer Survivors 2008 ·Health Communication ·Donald J. Cegala, Robert R. Bahnson, Steven K. Clinton, Prabu David, Michael Gong, J. Paul Monk, Subir Nag, Kamal S. Pohar	39
13	Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma 2007 ·Nature Clinical Practice Nephrology ·(unknown), Anjali A. Satoskar, Tibor Nádasdy, J. Paul Monk, Brad H. Rovin	70
14	Naftifine 1991 ·Drugs ·J. Paul Monk, Rex N. Brogden	44
15	Mexiletine 1990 ·Drugs ·J. Paul Monk, Rex N. Brogden	62
16	Osteomyelitis of the symphysis pubis: a complication of cardiac catheterisation 1989 ·International Journal of Clinical Practice ·Robert Guthrie, J. Paul Monk	5
17	Enoxacin 1988 ·Drugs ·(unknown), J. Paul Monk	42
18	Sufentanil 1988 ·Drugs ·J. Paul Monk, Rosemary Beresford, Alan Ward	89
19	Anisoylated Plasminogen Streptokinase Activator Complex (APSAC) 1987 ·Drugs ·J. Paul Monk, R.C. Heel	45
20	Ceforanide 1987 ·Drugs ·Deborah M. Campoli-Richards, Thomas E. Lackner, J. Paul Monk	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact